Ontology highlight
ABSTRACT: Objectives
For patients with a reduced left ventricular ejection fraction (LVEF) heart failure with reduced ejection fraction (HFrEF) and iron deficiency, administration of intravenous iron improves symptoms, exercise capacity and may in the following 12 months, reduce hospitalisations for heart failure. The Effectiveness of Intravenous iron treatment versus standard care in patients with heart failure and iron deficiency (IRONMAN) trial evaluated whether the benefits of intravenous iron persist in the longer term and impact on morbidity and mortality.Methods
IRONMAN is a prospective, randomised, open-label, blinded endpoint (PROBE) event-driven trial. Patients aged ≥18 years with HFrEF (LVEF ≤45%) and evidence of iron deficiency (ferritin <100 µg/L and/or TSAT <20%) were enrolled if they had either a current or recent hospitalisation for heart failure or elevated plasma concentrations of a natriuretic peptide. Participants were randomised to receive, or not to receive, intravenous ferric derisomaltose in addition to guideline-recommended therapy for HFrEF. Every 4 months, intravenous iron was administered if either ferritin was <100 µg/L or, provided ferritin was ≤400 µg/L, TSAT was <25%. The primary endpoint is a composite of total hospitalisations for heart failure and cardiovascular death. Hospitalisation and deaths due to infection are safety endpoints.Results
Trial recruitment was completed across 70 UK hospital sites in October 2021. Participants were followed until the end of March 2022. We plan to report the results by November 2022.Conclusions
IRONMAN will determine whether repeated doses of intravenous ferric derisomaltose are beneficial and safe for the long-term treatment of a broad range of patients with HFrEF and iron deficiency.Trial registration number
NCT02642562.
SUBMITTER: Kalra PR
PROVIDER: S-EPMC9726969 | biostudies-literature | 2022 Nov
REPOSITORIES: biostudies-literature
Kalra Paul R PR Cleland John Gf JG Petrie Mark C MC Ahmed Fozia Z FZ Foley Paul Wx PW Kalra Philip A PA Lang Ninian N NN Lane Rebecca E RE Macdougall Iain C IC Pellicori Pierpaolo P Pope Michael T B MTB Robertson Michele M Squire Iain B IB Thomson Elizabeth A EA Ford Ian I
Heart (British Cardiac Society) 20221124 24
<h4>Objectives</h4>For patients with a reduced left ventricular ejection fraction (LVEF) heart failure with reduced ejection fraction (HFrEF) and iron deficiency, administration of intravenous iron improves symptoms, exercise capacity and may in the following 12 months, reduce hospitalisations for heart failure. The Effectiveness of <i>I</i>nt<i>r</i>avenous ir<i>on</i> treat<i>m</i>ent versus standard care in p<i>a</i>tie<i>n</i>ts with heart failure and iron deficiency (IRONMAN) trial evaluate ...[more]